TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET END USER COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 67
4.2 PORTERS FIVE FORCES 68
5 INDUSTRY INSIGHTS 69
6 EPIDEMIOLOGY 70
7 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 71
7.1 REGULATORY SCENARIO IN THE U.S 71
7.2 REGULATORY SCENARIO IN AUSTRALIA 72
7.3 REGULATORY SCENARIO IN JAPAN 72
7.4 REGULATORY SCENARIO IN CHINA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 GROWING PREVALENCE OF THROAT CANCER 76
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 76
8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 77
8.2 RESTRAINTS 77
8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 77
8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 77
8.3 OPPORTUNITIES 78
8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 78
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 79
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
8.4 CHALLENGES 80
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 80
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
9 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
9.1 OVERVIEW 82
9.2 INSTRUMENTS 85
9.2.1 PATHOLOGY-BASED INSTRUMENTS 86
9.2.1.1 PCR INSTRUMENTS 86
9.2.1.2 SLIDE STAINING SYSTEMS 86
9.2.1.3 TISSUE PROCESSING SYSTEMS 87
9.2.1.4 CELL PROCESSORS 87
9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
9.2.2 IMAGING INSTRUMENTS 87
9.2.2.1 ULTRASOUND SYSTEMS 87
9.2.2.2 CT SYSTEMS 87
9.2.2.3 MRI SYSTEMS 87
9.2.2.4 OTHERS 88
9.2.3 BIOPSY INSTRUMENTS 88
9.2.4 OTHERS 88
9.3 CONSUMABLES & ACCESSORIES 88
9.3.1 KITS 89
9.3.1.1 PCR KITS 89
9.3.1.2 DNA POLYMERASE KITS 89
9.3.1.3 NUCLEIC ACID ISOLATION KITS 89
9.3.1.4 OTHERS 90
9.3.2 REAGENTS 90
9.3.2.1 ASSAYS 90
9.3.2.2 BUFFERS 90
9.3.2.3 PRIMERS 90
9.3.2.4 OTHERS 90
9.3.3 PROBES 90
9.3.4 OTHER CONSUMABLES 90
10 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
10.1 OVERVIEW 92
10.2 IMAGING TEST 95
10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
10.2.2 MRI 96
10.2.3 CHEST X-RAY 96
10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 96
10.2.5 OTHERS 96
10.3 BLOOD TEST 96
10.3.1 BLOOD CHEMISTRY TESTS 98
10.3.2 COMPLETE BLOOD COUNT (CBC) 98
10.3.3 OTHERS 98
10.4 BIOPSY 98
10.4.1 ENDOSCOPIC BIOPSY 99
10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 99
10.4.3 OTHERS 99
10.5 OTHERS 100
11 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 101
11.1 OVERVIEW 102
11.2 PHARYNGEAL CANCER 105
11.2.1 NASOPHARYNGEAL CANCER 106
11.2.2 OROPHARYNGEAL CANCER 106
11.2.3 HYPOPHARYNGEAL CANCER 106
11.3 LARYNGEAL CANCER 107
12 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 108
12.1 OVERVIEW 109
12.2 STAGE III 112
12.3 STAGE II 112
12.4 STAGE IV 113
12.5 STAGE I 114
12.6 STAGE 0 115
13 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY AGE 116
13.1 OVERVIEW 117
13.2 30-65 120
13.3 65 AND ABOVE 121
13.4 21-29 121
13.5 BELOW 21 122
14 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY END USER 123
14.1 OVERVIEW 124
14.2 HOSPITALS 127
14.3 ASSOCIATED LABS 127
14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 128
14.5 DIAGNOSTIC IMAGING CENTERS 129
14.6 CANCER RESEARCH INSTITUTES 130
14.7 OTHERS 131
15 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 132
15.1 OVERVIEW 133
15.2 DIRECT TENDER 136
15.3 RETAIL SALES 137
16 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, BY REGION 138
16.1 MIDDLE EAST AND AFRICA 139
16.1.1 SAUDI ARABIA 150
16.1.2 U.A.E 155
16.1.3 SOUTH AFRICA 160
16.1.4 EGYPT 165
16.1.5 ISRAEL 170
16.1.6 REST OF MIDDLE EAST AND AFRICA 175
17 MIDDLE EAST & AFRICA THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 176
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 176
18 SWOT ANALYSIS 177
19 COMPANY PROFILE 178
19.1 F. HOFFMANN- LA ROCHE LTD 178
19.1.1 COMPANY SNAPSHOT 178
19.1.2 REVENUE ANALYSIS 178
19.1.3 COMPANY SHARE ANALYSIS 179
19.1.4 PRODUCT PORTFOLIO 179
19.1.5 RECENT DEVELOPMENT 179
19.2 FUJIFILM CORPORATION 180
19.2.1 COMPANY SNAPSHOT 180
19.2.2 REVENUE ANALYSIS 180
19.2.3 COMPANY SHARE ANALYSIS 181
19.2.4 PRODUCT PORTFOLIO 181
19.2.5 RECENT DEVELOPMENT 181
19.3 THERMO FISHER SCIENTIFIC INC. 182
19.3.1 COMPANY SNAPSHOT 182
19.3.2 REVENUE ANALYSIS 182
19.3.3 COMPANY SHARE ANALYSIS 183
19.3.4 PRODUCT PORTFOLIO 183
19.3.5 RECENT DEVELOPMENTS 183
19.4 CANON MEDICAL SYSTEMS CORPORATION 184
19.4.1 COMPANY SNAPSHOT 184
19.4.2 REVENUE ANALYSIS 184
19.4.3 COMPANY SHARE ANALYSIS 185
19.4.4 PRODUCT PORTFOLIO 185
19.4.5 RECENT DEVELOPMENT 185
19.5 KONINKLIJKE PHILIPS N.V. 186
19.5.1 COMPANY SNAPSHOT 186
19.5.2 REVENUE ANALYSIS 186
19.5.3 COMPANY SHARE ANALYSIS 187
19.5.4 PRODUCT PORTFOLIO 187
19.5.5 RECENT DEVELOPMENT 188
19.6 ABBOTT 189
19.6.1 COMPANY SNAPSHOT 189
19.6.2 REVENUE ANALYSIS 189
19.6.3 PRODUCT PORTFOLIO 190
19.6.4 RECENT DEVELOPMENTS 190
19.7 AGILENT TECHNOLOGIES, INC. 191
19.7.1 COMPANY SNAPSHOT 191
19.7.2 REVENUE ANALYSIS 191
19.7.3 PRODUCT PORTFOLIO 192
19.7.4 RECENT DEVELOPMENT 192
19.8 BD 193
19.8.1 COMPANY SNAPSHOT 193
19.8.2 REVENUE ANALYSIS 193
19.8.3 PRODUCT PORTFOLIO 194
19.8.4 RECENT DEVELOPMENTS 194
19.9 BEIJING O&D BIOTECH CO., LTD. 195
19.9.1 COMPANY SNAPSHOT 195
19.9.2 PRODUCT PORTFOLIO 195
19.9.3 RECENT DEVELOPMENT 195
19.10 BIO-RAD LABORATORIES, INC. 196
19.10.1 COMPANY SNAPSHOT 196
19.10.2 REVENUE ANALYSIS 196
19.10.3 PRODUCT PORTFOLIO 197
19.10.4 RECENT DEVELOPMENT 197
19.11 FONAR CORP. 198
19.11.1 COMPANY SNAPSHOT 198
19.11.2 REVENUE ANALYSIS 198
19.11.3 PRODUCT PORTFOLIO 199
19.11.4 RECENT DEVELOPMENT 199
19.12 GE HEALTHCARE 200
19.12.1 COMPANY SNAPSHOT 200
19.12.2 REVENUE ANALYSIS 200
19.12.3 PRODUCT PORTFOLIO 201
19.12.4 RECENT DEVELOPMENT 201
19.13 HOLOGIC INC. 202
19.13.1 COMPANY SNAPSHOT 202
19.13.2 REVENUE ANALYSIS 202
19.13.3 PRODUCT PORTFOLIO 203
19.13.4 RECENT DEVELOPMENT 203
19.14 ILLUMINA, INC. 204
19.14.1 COMPANY SNAPSHOT 204
19.14.2 REVENUE ANALYSIS 204
19.14.3 PRODUCT PORTFOLIO 205
19.14.4 RECENT DEVELOPMENT 205
19.15 MEDONICA CO. LTD 206
19.15.1 COMPANY SNAPSHOT 206
19.15.2 PRODUCT PORTFOLIO 206
19.15.3 RECENT DEVELOPMENT 206
19.16 MERCK KGAA 207
19.16.1 COMPANY SNAPSHOT 207
19.16.2 REVENUE ANALYSIS 207
19.16.3 PRODUCT PORTFOLIO 208
19.16.4 RECENT DEVELOPMENT 208
19.17 MINFOUND MEDICAL SYSTEMS CO., LTD 209
19.17.1 COMPANY SNAPSHOT 209
19.17.2 PRODUCT PORTFOLIO 209
19.17.3 RECENT DEVELOPMENT 209
19.18 MYRIAD GENETICS, INC. 210
19.18.1 COMPANY SNAPSHOT 210
19.18.2 REVENUE ANALYSIS 210
19.18.3 PRODUCT PORTFOLIO 211
19.18.4 RECENT DEVELOPMENT 211
19.19 PLEXBIO 212
19.19.1 COMPANY SNAPSHOT 212
19.19.2 PRODUCT PORTFOLIO 212
19.19.3 RECENT DEVELOPMENT 212
19.20 QIAGEN 213
19.20.1 COMPANY SNAPSHOT 213
19.20.2 REVENUE ANALYSIS 213
19.20.3 PRODUCT PORTFOLIO 214
19.20.4 RECENT DEVELOPMENT 214
19.21 QUEST DIAGNOSTICS INCORPORATED 215
19.21.1 COMPANY SNAPSHOT 215
19.21.2 REVENUE ANALYSIS 215
19.21.3 PRODUCT PORTFOLIO 216
19.21.4 RECENT DEVELOPMENT 216

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.